Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633817 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL30510296 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL29398902 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL120595 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL120592 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL118926 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL30688517 | 0.95 | ITGB3 (0.44) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL25182226 | 0.93 | ITGB3 (0.42) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL25182320 | 0.93 | ITGB3 (0.42) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL25356271 | 0.93 | PPARG (0.43) | ITGB3ITGA2BFABP5FABP7PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117186189-A | GLP-1/CCK-1 receptor double-excitation polypeptide with hypoglycemic and weight-reducing effects and application thereof | 嘉兴学院 | 2023-12-08 | — | — | CN | claimed |
| US-12637494-B2 | Method for producing peptide containing non-natural amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-26 | — | — | US | disclosed |
| CN-119661656-B | Polypeptide of targeted antagonism pCAV1 and application thereof | 华中科技大学同济医学院附属梨园医院 | 2026-05-15 | — | — | CN | disclosed |
| US-20260116920-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | PEPTIDREAM INC. (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4667483-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING PEPTIDE | JCR Pharmaceuticals Co., Ltd. (JP) | 2025-12-24 | — | — | EP | disclosed |
| US-20250326865-A1 | C-MET PROTEIN-BINDING PEPTIDE COMPLEX | PEPTIDREAM INC. (JP) | 2025-10-23 | — | — | US | disclosed |
| EP-4631955-A1 | PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-02 | — | — | US | disclosed |
| US-20250298027-A1 | METHOD OF EVALUATING SMALL MOLECULE DISTRIBUTION USING TELLUROPHENE ANALOGUES | UNIVERSITY HEALTH NETWORK (CA) | 2025-09-25 | — | — | US | disclosed |
| EP-4026906-A1 | COMPOSITION FOR TRANSLATION, AND METHOD FOR PRODUCING PEPTIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-07-13 | — | — | EP | disclosed |
| CN-109134610-B | Peptide compound, application thereof and composition containing peptide compound | 尚华医药科技(江西)有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114630835-A | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2022-06-14 | — | — | CN | disclosed |
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| EP-3993874-A1 | CD38-BINDING AGENTS AND USES THEREOF | PeptiDream Inc. (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20220125891-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-04-28 | — | — | US | disclosed |
| CN-114269770-A | CD38 binding agents and uses thereof | 肽梦想株式会社 | 2022-04-01 | — | — | CN | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637494-B2 | Method for producing peptide containing non-natural amino acid | MRPL21, RPL21, RPL30 | ITGB3 4429/4885ITGA2B 4446/4885FABP5 2147/4885 |
| US-20260116920-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | MET, TFRC, SLC7A1 | ITGB3 1252/4885ITGA2B 1214/4885FABP5 492/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | ITGB3 1361/4885ITGA2B 2376/4885FABP5 2537/4885 |
| US-20250326865-A1 | C-MET PROTEIN-BINDING PEPTIDE COMPLEX | MLX, METTL16, GC | ITGB3 4696/4885ITGA2B 4680/4885FABP5 74/4885 |
| US-20250298027-A1 | METHOD OF EVALUATING SMALL MOLECULE DISTRIBUTION USING TELLUROPHENE ANALOGUES | SNRPE, SNRPA, SLC5A7 | ITGB3 923/4885ITGA2B 1026/4885FABP5 3430/4885 |
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | ITGB3 2287/4885ITGA2B 1424/4885FABP5 638/4885 |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NGLY1, NPPA, NPEPPS | ITGB3 3772/4885ITGA2B 4363/4885FABP5 1733/4885 |
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | PCTP, CETP, PLTP | ITGB3 3832/4885ITGA2B 4507/4885FABP5 265/4885 |
| US-20220125891-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | RNASE1, IRAK1, SERBP1 | ITGB3 3345/4885ITGA2B 3840/4885FABP5 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.